君實生物(01877.HK):今年特瑞普利單抗銷售有望持續改善
君實生物(01877.HK)表示,2022年公司完成了對商業化團隊的調整、對營銷地域團隊的組建恢復工作,並補充了核心市場人員。盡管階段性受到疫情影響,相較於2021年度,特瑞普利單抗2022年度銷售收入仍實現了按年顯著增長。
在適應癥方面,特瑞普利單抗2022年新增一線食管鱗癌及一線非小細胞肺癌兩項大適應癥,隨著期內商業化能力提升,以及大適應癥開始逐步獲批,公司在內地市場的銷售情況已逐步進入正向循環。
公司表示,由今年起,特瑞普利單抗的銷售有望持續改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.